Best timing for hepatitis B vaccine after transplant
Part of Digestive system, Infections clinical trials.
This trial looks at the best time to give the hepatitis B vaccine to people who have had a stem cell transplant and are in remission. It may help find the safest and most effective timing for vaccination.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older
- You have received a stem cell transplant (hematopoietic cell transplant)
- Your cancer or blood disease is in complete molecular remission (no signs of disease)
- You have not had more than one transplant
- You did not have hepatitis B (positive HBsAg or HBV-DNA) before or within 3 months after transplant, and your donor also did not have hepatitis B
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving the hepatitis B vaccine to full-term newborns who had multiple stomach or intestine surgeries is safe and works well. It aims to protect these babies from hepatitis B infection.
This study helps doctors predict which patients might experience hepatitis B reactivation (a flare-up of a past infection) after receiving a stem cell transplant. By understanding your risk, doctors can monitor you more closely and potentially prevent serious complications.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
This early-phase study tests whether a hepatitis B vaccine (with an added ingredient to boost the immune response) can safely help people with long-term hepatitis B who are already on antiviral therapy. It is mainly looking at safety and how the immune system responds.
This study tests a vaccine strategy for people who are being evaluated and waiting for a liver transplant. The goal is to see how well the immune system responds and how the results are interpreted before transplant.
This study tests an added hepatitis B immune medicine (HBV immunoglobulin) in people with chronic hepatitis B who have liver cancer and are planning surgery or a liver transplant. The goal is to see if giving this protection around the time of treatment can help prevent liver cancer from coming back or worsening.
Hear when a new Transplant-Related Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.